Immuno-Oncology

The AJMC^® Immuno-Oncology compendium is a comprehensive resource for clinical news and expert insights for treatments that utilize the body's immune system to fight cancer, such as immune checkpoint inhibitors and chimeric antigen receptor T-cell therapies.

Latest News

Blinatumomab Approved in Consolidation Phase for CD-19+ Ph-Negative Precursor B-ALL, “Redefines Standard of Care”

June 14th 2024

Bringing the bispecific T-cell engager into the frontline consolidation phase "redefines the standard of care" for patients with B-ALL, an investigator said.

Esophageal cancer illustration | Image credit: Dr_Microbe - stockadobe.com

Tislelizumab Plus Chemo Meaningfully Improves OS, PFS in Advanced Esophageal Cancer

By Laura Joszt, MA

June 14th 2024

CAR T-cell therapy | Image credit: Getty Images Science Library

Whither CAR T? Will the FDA Being Under the Hood and the Availability of Bispecifics Make These Therapies Less Attractive?

By Sang Chau, PharmD, BCOP
Justin Tse, PharmD, BCOP

June 12th 2024

Older male patient speaking with doctor | Image credit: DragonImages - adobe.stock.com

Dr Christopher Flowers: Liso-Cel Approval for Mantle Cell Lymphoma Changes the Treatment Strategy

By Mary Caffrey
Laura Joszt, MA

June 7th 2024

Breyanzi packaging | Image credit: BMS

FDA Approves Liso-Cel to Treat R/R Mantle Cell Lymphoma

By Mary Caffrey

May 30th 2024

More News

Pembrolizumab Improved OS, PFS as First-Line Treatment in NSCLC

May 30th 2018

Pembrolizumab Improved OS, PFS as First-Line Treatment in NSCLC

Jaime Rosenberg

Pembrolizumab significantly improved overall survival (OS) and progression-free survival (PFS) as first-line treatment for squamous non–small cell lung cancer (NSCLC) in the pivotal phase 3 KEYNOTE-407 trial.

Immune Checkpoint Inhibitors Demonstrate Better Response in Men Than Women

May 17th 2018

Immune Checkpoint Inhibitors Demonstrate Better Response in Men Than Women

Jaime Rosenberg

While immune checkpoint inhibitors significantly improve overall survival in both sexes, the magnitude of benefit is dependent on sex, according to new study findings.

Study Finds Rapid Uptake of Anti–PD-1 Agents Following FDA Approval

May 14th 2018

Study Finds Rapid Uptake of Anti–PD-1 Agents Following FDA Approval

Jaime Rosenberg

In the 4 months following their approvals, pembrolizumab and nivolumab reached more than 60% of eligible patients with melanoma, non-small cell lung cancer, and renal cell carcinoma.

CAR T Therapy Case Study Shows Early Success in Treatment of Acute Myeloid Leukemia

May 9th 2018

CAR T Therapy Case Study Shows Early Success in Treatment of Acute Myeloid Leukemia

Samantha DiGrande

A new case study found that an acute myeloid leukemia patient has remained cancer free for 9 months following treatment with the chimeric antigen receptor (CAR) T-cell treatment, CYAD-01, and a bone marrow transplant.

FDA Approves CAR T-Cell Treatment Kymriah for Adult B-Cell Lymphoma

May 2nd 2018

FDA Approves CAR T-Cell Treatment Kymriah for Adult B-Cell Lymphoma

Jaime Rosenberg

Tisagenlecleucel, sold as Kymriah, has gained its second indication following the FDA's approval of the chimeric antigen receptor T-cell therapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma, the most common form of non-Hodgkin lymphoma.

FDA Grants Priority Review for Pembrolizumab, Chemotherapy Combination in NSCLC

April 30th 2018

FDA Grants Priority Review for Pembrolizumab, Chemotherapy Combination in NSCLC

Jaime Rosenberg

The FDA has granted priority review to Merck’s supplemental Biologics License Application for pembrolizumab (Keytruda) in combination with pemetrexed (Alimta) and platinum chemotherapy as first-line treatment for patients with metastatic nonsquamous non–small cell lung cancer (NSCLC). The FDA is set to make a decision by September 23.

April 21st 2018

Dr Houston Holmes Discusses CAR T Therapy Adoption and Education

Laura Joszt, MA

With chimeric antigen receptor (CAR) T-cell therapy being so new, there is going to be a learning curve as providers become more educated about the treatments, the manufacturing process, and the toxicities, Houston Holmes, MD, MBA, FACP, a medical oncologist with Texas Oncology, explained at the Community Oncology Alliance’s (COA) 2018 Community Oncology Conference.

February 25th 2018

Future Shock: Embracing Disruption in the Immunotherapy Revolution

Joseph Alvarnas, MD

Dr Alvarnas is editor in chief and director of Value-Based Analytics at City of Hope, Duarte, California.

February 21st 2018

Current Landscape of Immuno-Oncology in Advanced Melanoma

February 21st 2018

Contemporary Diagnosis and Management of Advanced Melanoma

February 21st 2018

Exploring the Economic Implications of Immuno-Therapy

February 21st 2018

Clinical Perspectives in the Evolving Role of Immuno-Oncology Treatment With Jason J. Luke, MD, FACP

February 21st 2018

Provocative Questions, Better Biomarkers, and the Prospect of Triple Therapy: A Conversation With NYU's Jeffrey S. Weber, MD, PhD

Ipililumumab's role in treating melanoma will change, as the immunotherapy will likely become part of different combinations than we see today.

Single-Agent Ipilimumab Ineffective in HPV-Related Advanced Cervical Cancer

November 30th 2017

Single-Agent Ipilimumab Ineffective in HPV-Related Advanced Cervical Cancer

Surabhi Dangi-Garimella, PhD

Analysis of the results from an early phase multicenter study have found that while ipilimumab is safe in women with metastatic or recurrent cervical cancer, it did not improve patient response to treatment.

August 4th 2017

5 Developments With Cancer Immunotherapy

Surabhi Dangi-Garimella, PhD

There’s a lot happening in clinical practice with immunotherapy treatments: expanded indications for nivolumab and ipilimumab, biomarkers to judge patient response to combinations, and developments with CAR-T.

May 3rd 2017

PD-1 and PD-L1 Inhibitors Could Effectively Treat Advanced Sarcomas, Cancer Study Suggests

Surabhi Dangi-Garimella, PhD

Researchers have identified specific characteristics that can help identify responsiveness of patients with soft tissue sarcomas to immunotherapy.

April 10th 2017

Do We Need Biomarkers to Predict Tumor Hyper-Progression Following Immunotherapy?

Surabhi Dangi-Garimella, PhD

A new study published in Clinical Cancer Research provides evidence that researchers can use biomarkers to identify patients whose tumors will grow at a faster rate following immunotherapy treatment.

March 7th 2017

Study Compares Cost-Effectiveness of Immune Checkpoint Inhibitors in Advanced Melanoma

First-line pembrolizumab every 3 weeks followed by second-line ipilimumab, and first-line nivolumab followed by second-line ipilimumab are cost-effective strategies in patients with advanced melanoma expressing wild-type BRAF.

January 24th 2017

Study Reveals Why Immuno-Oncology Treatments Are Effective in Only a Minority of Patients

Surabhi Dangi-Garimella, PhD

A system-wide immune response, not just a local response limited to the tumor, is what determines successful remission following cancer immunotherapy.

January 17th 2017

MYSTIC Trial, Evaluating Durvalumab as First-Line in NSCLC, Adds OS Endpoint

Surabhi Dangi-Garimella, PhD

The trial, evaluating the programmed death ligand-1 inhibitor durvalumab, alone or in combination with tremelimumab, versus platinum-based chemotherapy, has refined its endpoints to include overall survival (OS) along with progression-free survival.

November 23rd 2016

5 Key Highlights From the Patient-Centered Oncology Care Meeting

Surabhi Dangi-Garimella, PhD

Here's a glimpse into what The American Journal of Managed Care’s 5th annual Patient-Centered Oncology CareÂ® meeting had in store for its attendees.

November 21st 2016

PCOC16: Immunoâ€Oncology Agents in a World of Precision Medicine

Surabhi Dangi-Garimella, PhD

At the 5th annual meeting of Patient-Centered Oncology CareÂ®, hosted by The American Journal of Managed Care, November 17-18 in Baltimore, Maryland, experts with diverse experiences and backgrounds discussed the contradiction presented by immuno-oncology agents in the world of precision medicine.

November 7th 2016

Meta-Analysis Confirms Clinical Advantage of BRAF/MEK and PD-1 Inhibitors in Melanoma

Surabhi Dangi-Garimella, PhD

Based on a retrospective meta-analysis of clinical trial data, authors of a recent paper in JAMA Oncology concluded that BRAF/MEK and programmed death receptor-1 (PD-1) inhibitors were the most effective treatments that were relatively safe in melanoma.

October 31st 2016

Phase I Study Indicates Pembrolizumab an Option in Heavily Pretreated Hodgkin Lymphoma

A small, early-stage study in patients with Hodgkin lymphoma who had failed multiple treatments or relapsed after stem cell transplant indicates that pembrolizumab could be a favorable treatment option in these patients.

October 28th 2016

Study Results Could Help Strengthen Response to Checkpoint Inhibitors

Surabhi Dangi-Garimella, PhD

An animal study conducted at the Perelman School of Medicine, University of Pennsylvania, has identified a mechanism to strengthen the immune response of T cells in cancer patients who are treated with checkpoint inhibitors.

October 25th 2016

Pembrolizumab Is FDA-Approved as First-Line for PD-L1—Positive NSCLC

Patients newly diagnosed with non—small cell lung cancer (NSCLC) that expresses the programmed death ligand-1 (PD-L1) protein now have a new treatment option: pembrolizumab (Keytruda).

October 19th 2016

First PD-L1 Inhibitor Approved as Second-Line Treatment for NSCLC

Surabhi Dangi-Garimella, PhD

Atezolizumab, an inhibitor of the programmed death ligand-1 protein, has been approved for the treatment of patients with non-small cell lung cancer who failed to respond to treatment with platinum-based chemotherapy.

October 10th 2016

Nivolumab Disappoints, Pembrolizumab May Replace Chemotherapy in Advanced NSCLC

Surabhi Dangi-Garimella, PhD

While nivolumab failed to surpass the outcomes of chemotherapy as first-line treatment in programmed death ligand-1—expressing patients with non-small cell lung cancer (NSCLC), pembrolizumab bettered chemotherapy in improving survival in a similar cohort.

October 5th 2016

Following Nivolumab, NICE Rejects Pembrolizumab for Use in Patients With NSCLC

Surabhi Dangi-Garimella, PhD

A draft guidance issued by the National Institute for Health and Care Excellence (NICE) rejected use of Merck's programmed death-1 inhibitor pembrolizumab (Keytruda) in patients diagnosed with non-small cell lung cancer (NSCLC).

October 4th 2016

The Power of an Immuno-oncology Collaborative Care Team

Surabhi Dangi-Garimella, PhD

At the Institute for Clinical Immuno-Oncology National Conference, a panel of care providers presented institutional experiences with immunotherapy, and how a collaborative care approach helped the process.

...

8 9 10 11 12 13 14 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions